

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK Washington, D.C. 20231

APPLICATION NUMBER ATTORNEY DOCKET NO. FILING DATE FIRST NAMED APPLICANT 10/12/100 **EXAMINER** ennet ART UNIT PAPER NUMBER 1015 11 **DATE MAILED:** INTERVIEW SUMMARY All participants (applicant, applicant's representative, PTO personnel): Date of Interview_ Personal (copy is given to applicant applicant's representative). Type: Telephonic Televideo Conference Exhibit shown or demonstration conducted: Very No If yes, brief description: Agreement Wwas reached. was not reached. Priscant Identification of prior art discussed:_ Description of the general nature of what was agreed to if an agreement was reached, or any other comments. appear (A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.) It is not necessary for applicant to provide a separate record of the substance of the interview. Uhless the paragraph above has been checked to indicate to the contrary. A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has are ready been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. Examiner Note: You must sign this form unless it is an attachment to another form.

1. A method for treating a bacterial infection to a patient, the method comprising:

administering to the patient in need thereof a composition in solid form comprising amoxicillin and potassium clavulanate and comprising a first release phase and a second release phase;

the first release phase comprising potassium clavulanate and a first portion of the amoxicillin;

the second release phase comprising a second portion of amoxicillin, which is a pharmaceutically acceptable soluble salt of amoxicillin, and at least one pharmaceutically acceptable organic acid which are admixed in intimate contact at a ratio of from 50:1 to 1:5 (amoxicillin free acid equivalent to organic acid equivalent).

Proposed